Breast cancer is the most common cancer among women all over the world. Since the clinical outcome of breast cancer may differ among some women who have the same clinicopathological stage, researchers focused on additional prognostic parameters to predict the tumor behavior. The aim of this study was to investigate the prognostic value of Wilms Tumor 1 (WT1) expression in tumor tissues and to compare it with known prognostic variables in patients with breast cancer. In patients with breast cancer, we investigated the relationship between (WT1) protein expression in tumor and surrounding tissues and prognostic variables including age, pathologic type, axillary node involvement, estrogen receptor (ER) status, menopausal status, stage (TNM), tumor grade and treatment. Borderline significance was detected between WT1 monoclonal antibody (mAb) staining and premenopausal state (p=0.051). Additionally, surrounding tissue staining showed significant correlations with grade (p=0.045), stage (p=0.026), lymph node status (p=0.026), and axillary involvement (p=0.02), respectively. No correlation was demonstrated between relapse free survival, relapse sites and WT1 mAb staining of tumor and surrounding tissues (p=0.36). WT1 mAb staining was demonstrated in human breast cancer tissues, and in this study we have used monoclonal antibody against WT1 on paraffin-embedded tissue samples. The results indicate that WT1 expression by tumor is more evident in premenopausal state rather than postmenopausal period. To confirm the results, we need large scale studies on WT1 expression in breast cancer. Keywords: Breast cancer; immunohistochemistry; prognosis; premenopausal; WT1 Özet Meme kanseri tüm dünyada kadınlarda görülen en sık kanser tipidir. Aynı klinikopatolojik evredeki kadınlarda meme kanserinin klinik seyri farklı olabilir, bu yüzden araştırmacılar tümör davranışını tahmin edebilmek için ek prognostik parametrelere odaklanmışlardır. Bu çalışmanın amacı, meme kanseri hastalarında tümör dokusunda Wilms Tumor 1 (WT1) ekspresyonunun prognostik önemi ve bunun bilinen prognostik değişkenlerle karşılaştırılmasıdır. Meme kanserli hastalarda, tümor ve tümör dokusu çevresindeki dokularda WT1 protein ekspresyonu ile prognostik faktörlerden yaş, patolojik tip, aksiller lenf nodu tutulumu, östrojen reseptör (ER) durumu, menopoz durumu, evre (TNM), tümör gradı ve tedavi arasındaki ilişki araştırıldı. WT1 monoklonal antikor (mAb) ile premenopozal durum arasında orta derecede bir ilişki saptandı (p=0.051). Ek olarak, tümör çevresindeki doku ile tümör gradı (p=0.045), evre (p=0.026), lenf nodu (p=0.026) ve aksiller tutulum (p=0.02) arasında anlamlı ilişki saptandı. Nükssüz sağkalım, nüks bölgeleri ile tümör dokusu ve tümör çevresi dokudaki WT1 mAb arasında anlamlı ilişki gözlenmedi (p=0.36). İnsan meme kanseri dokularında WT1 mAb gösterilmiştir ve bu çalışmada parafindeki doku örneklerine karşı monoklonal antikorlar kullanıldı. Bu sonuçlar premenopozal dönemde tümör dokusunda WT1 ekspresyonunun postmenopozal döneme göre daha fazla olduğunu göstermektedir. Bu sonuçların teyid edilmesi için meme kanserinde WT1 ekspresyonu için daha büyük çalışmalara ihtiyaç vardır.
Introduction
Breast cancer is the most common cancer among women all over the world. Despite the improvements in diagnosis and therapy, breast cancer has still high morbidity and mortality rates. Since the clinical outcome of breast cancer may differ among some women who have the same clinicopathological stage, researchers focused on additional prognostic parameters to predict the tumor behavior. As cure is not possible in patients with advanced stage or relapsed disease after primary therapy, and only palliation can be achieved with chemoradiotherapy and/or other treatment modalities, the most important point is to predict the patients who will benefit from adjuvant chemo and/or radiotherapy, especially in the early stage. Wilms tumor 1 (WT1) gene was originally isolated as a tumor suppressor gene. The expression of WT1 is limited to kidney, testis, ovary, hematopoietic and myoepithelial progenitor cells in postnatal life and WT1 is overexpressed in approximately 90% of breast cancers (1) . The aim of this study was to investigate the prognostic value of WT1 gene expression in tumor tissues and to compare it with known prognostic variables in patients with breast cancer.
Material and Methods
Sixty-six biopsy samples of breast cancer were included in this study. 
Results
Demographical, clinical and pathological parameters of patients were illustrated in Tables 1 and 2 . WT1 mAb staining was shown in Figure 1 . Figure 1 . WT1 monoclonal antibody staining in fetal kidney (x100) (A), WT1 monoclonal antibody staining sparse cytoplasmic staining (x400) (B), WT1 monoclonal antibody staining dense cytoplasmic staining (x400) (C), WT1 monoclonal antibody staining in surrounding normal appearing tissue (x400) (D). WT1 monoclonal antibody staining in fetal kidney has been shown in Figure 1A . Both sparse and intense cytoplasmic (without nuclear) staining were detected in tumor samples ( Figures 1B and 1C ). Intense cytoplasmic and nuclear staining were detected at the surrounding normal appearing tissue ( Figure 1D ). All samples were re-evaluated and graded and results were illustrated in Table 3 .
Correlation between clinicopathological features and WT1 mAb staining were calculated with Chi-square and Fisher's exact tests and results were shown in Table 4 . Borderline significance was detected between WT1 mAb staining at tumor tissue and premenopausal status (p=0.051) (56% for premenopausal, 40% for postmenopausal). In addition, surrounding tissue staining showed significant correlation between WT1 mAb staining and grade (p=0.045), stage (p=0.026), lymph node status (p=0.026) and axillary involvement (p=0.02), respectively. Subgroup analyses were illustrated in Table 5 . No correlations between relapse free survival, relapse sites and WT1 mAb staining of tumor and surrounding tissues were found (p=0.36).
Discussion
Breast carcinoma is the most common tumor among women that causes morbidity and mortality. Some clinical and pathological prognostic parameters including histopathologic type, grade, steroid receptor status, TNM staging, menopausal status and cell cycle parameters (mitotic index, S-phase fraction, Ki67, PCNA, etc) was used for this purpose (2) . These parameters are valuable in clinical practice but not ideal to predict the clinical outcome in all patients. For this reason it is important to detect the additional predictive factors determining the biology of the breast cancer.
Tumor suppressor gene activities have been widely studied in breast cancer. nm23 and p53 are the most commonly studied genes, and a correlation has been shown between good prognosis and normal expression (3) (4) (5) (6) (17) showed that the expression of WT1 gene may be an indicator of poor prognosis in patients with advanced serous epithelial ovarian carcinoma. Ninety nine patients were included in this study and 50.5% of patients showed WT1 staining. Five-year survival of non-staining patients and staining patients were 39.4% and 10.7% (p < 0.00005); five-year recurrence-free survival of these patients were 29.8% and ≤ 7.5% (p < 0.00005), respectively (17) .
Wilms tumor 1 is overexpressed in approximately 90% of breast cancers (1). WT1 protein can suppress the transcription of some of the genes induced by growth factors. For example, the genes encoding insulin-like growth factor 1 (IGF-1) and epidermal growth factor receptor are thought to be a target for WT1. The IGF-1 receptor is important for the development and progression of breast cancer and IGF-1 receptor is downregulated by some transcription factors like WT1 protein (18) . Expression of growth factors increases after WT1 inactivation and results in cell proliferation (19) . Regulation of WT1 transcription is dependent on wild type p53. In the absence of this, WT1 will act as a transcription activator rather than suppressor (20) . Reizner et al. showed that WT1 suppresses IGF-IR gene transcription in breast cancer cells and there was an association with estrogen receptor alpha. This finding suggested the potential role of the tumor suppressor activity of WT1 in breast cancer (21) . However, another study showed that WT1 protein plays a role in progression and apoptosis on HER2/neu-overexpressing breast cancer cells. The decreased expression of WT1 led to cell cycle arrest at G1 phase and increased apoptosis in HER2/neu-overexpressing breast cancer cells and this act was correlated with decreased cyclin D1 and Bcl-2 levels (22).
Overexpression of WT1 is associated with poor prognosis, especially worse 5-year disease-free survival in breast cancer (23) . A study showed overexpression of WT1 at drug resistance cells after cytotoxic treatment (24) . Levels of WT1 are correlated with proliferation of breast cancer cells and WT1 expression increase during proliferation of breast cancer cells stimulated by 17 betaestradiol. If proliferation of cancer cells are inhibited by tamoxifen or all-trans-retinoic acid, the expression of WT1 decreased (25 
